Akzo Nobel NV AKZO NOBEL ORD SHS/ NL0013267909 /
5/24/2024 6:18:03 PM | Chg. - | Volume | Bid5:40:12 PM | Ask5:40:12 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
64.46EUR | - | 634,519 Turnover: 1.65 mill. |
-Bid Size: - | -Ask Size: - | 10.74 bill.EUR | 3.14% | 24.04 |
GlobeNewswire
8/27
Focused on Youth, Forward for Future: the 2024 WLA Forum Sustains to Support the Development of Yout...
GlobeNewswire
8/19
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Inv...
GlobeNewswire
8/19
Qubit Pharmaceuticals nominated for "Best start-up" award at Prix Galien USA 2024
GlobeNewswire
8/13
Alliance for Decision Education Announces Grant to Advance Decision-Making Research
GlobeNewswire
8/12
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman
GlobeNewswire
8/12
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
GlobeNewswire
8/9
Ushering in a New Phase: E China's Wuxi Hosts 2024 Taihu Talent Development Conference
GlobeNewswire
8/8
Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
GlobeNewswire
8/7
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
GlobeNewswire
8/6
Pattern CEO Joins Nobelists and Global Leaders Looking Toward the Next Decade in the International R...
GlobeNewswire
7/24
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
GlobeNewswire
7/17
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Pop...